Alipogene Tiparvovec for the Treatment of LPLD Patients
An Open Label, Multi-centre Trial of Alipogene Tiparvovec for the Treatment of LPLD Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke
-
-
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, PA19104
- Perelman School of Medicine at The University of Pennsylvania Translational Medicine & Human Genetics
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Main inclusion criteria are:
- Patients with a history of severe or multiple pancreatitis attacks despite dietary fat restriction.
- Genetically confirmed diagnosis of LPLD
- Post-heparin plasma LPL protein mass > 5% of normal
- LPL activity ≤20% of normal (in post- heparin plasma)
- Fasting plasma TG concentration >10 mmol/L.
Main exclusion criteria are:
- Females with a positive pregnancy test or who are breastfeeding, or on contraceptive use.
- Patients with a positive HIV, Hepatitis B, Hepatitis C or being positive for tuberculosis.
- Patients under treatment with antiplatelet or other anti-coagulants.
- Patient allergic to or having a condition that prohibits the use of immunosuppressants.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: alipogene tiparvovec with IS
Patients in the Immuno+ group will receive an immunosuppressant regimen to be initiated three days prior to alipogene tiparvovec administration.
The regimen is to be continued for 12 weeks: Cyclosporins (3 mg/kg/day) and mycophenolate mofetil (2 x 1 g/day).
Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
|
A dose of 1x10(*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.
Other Names:
IV bolus methylprednisolone 1mg/kg half hour prior to administration
Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration
Immuno + group will receive Mycophenolate mofetil (2x 1 g/day) from three days prior to until 12 weeks following IMP administration
|
|
Other: alipogene tiparvovec without IS
Patients in the Immuno- group will not receive an immunosuppressant regimen during 12 weeks.
Patients will receive IV bolus of 1mg/kg of methyl Prednisolone half an hour prior to IMP administration.
|
A dose of 1x10(*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.
Other Names:
IV bolus methylprednisolone 1mg/kg half hour prior to administration
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Clinical Response of alipogene tiparvovec in LPLD patients
Time Frame: 2 years
|
The overall clinical response of alipogene tiparvovec in LPLD patients will be assessed compared to baseline, by a combination of measurements, of which each gives relevant information to obtain enough and solid evidence in a small trial.
Each of these outcome measures will be evaluated in combination with the results of other measures (to get an overall conclusion relating the clinical response).
Descriptive methods will be used (so no formal statistical analyses will be performed), due to the specific nature and the small sample size of a rare disease trial.
|
2 years
|
|
The long term effect of alipogene tiparvovec on post prandial metabolism of chylomicrons (ppCM) in LPLD patients.
Time Frame: 2 years
|
CM [3H]-activity will be assessed during ppCM testing pre- and post-dose, compared to baseline.
|
2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The effect of alipogene tiparvovec on postprandial metabolism of chylomicrons (ppCM) in LPLD patients with and without immunosuppression treatment, at 14 weeks post-administration.
Time Frame: Baseline, 14 weeks
|
CM [3H]-activity will be assessed during ppCM testing pre- and post-dose, compared to baseline.
|
Baseline, 14 weeks
|
|
Immuno response of alipogene tiparvovec by analysis of antibody formation
Time Frame: Baseline, 1 and 2 years post dose
|
The immuno response of alipogene tiparvovec will be assessed by measuring the antibody formation compared to baseline.
|
Baseline, 1 and 2 years post dose
|
|
Immuno response of alipogene tiparvovec by analysis of T-cell response
Time Frame: Baseline, 1 and 2 years post dose
|
T-cell responses against alipogene tiparvovec will be assessed by measuring the T-cell response compared to baseline.
|
Baseline, 1 and 2 years post dose
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: André Carpentier, MD, Centre de recherche du Centre Hospitalier Universitaire de Sherbrooke
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Genetic Diseases, Inborn
- Metabolism, Inborn Errors
- Lipid Metabolism Disorders
- Hyperlipidemias
- Dyslipidemias
- Lipid Metabolism, Inborn Errors
- Hyperlipoproteinemias
- Hyperlipoproteinemia Type I
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dermatologic Agents
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Antitubercular Agents
- Antibiotics, Antitubercular
- Calcineurin Inhibitors
- Prednisolone
- Mycophenolic Acid
- Cyclosporine
- Cyclosporins
Other Study ID Numbers
Other Study ID Numbers
- Gly-CD-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.